IMGN is no penny stock, it's a real Biotech Company with great asset value. This MS Analyst has an agenda. You should have averaged down on IMGN, it will be back above your purchase price!
I think this MS Analyst has an agenda to drive the market valuation down to a potential acquirers liking. How can he value as he did when IMGN has a rare asset as one of the few true MAB manufactures, a successful ADC platform and all the top pharma names using their technology with a total of 17 shots on goal! Is Morgan Standley smarter than Roche, Novartis, Sanofi, Bayer, Amgen, Lilly and BioTest?
Sentiment: Strong Buy
REGN was knocked down by analyst stating they were losing 10% of Eylea sales per month to competition. Was knocked down all the way to $276, then we learn that Sanofi increased their stake and it's back up to $315 as takeover rumors persist. This bearish call is not justified and driven by an analyst agenda in my opinion.
Sentiment: Strong Buy
If you're going to post info on non-CDRC info, please keep it to the space and make it good quality. Not pink sheet junk that trades under a penny!
We need to get that Morgan Stanley Bearish press release off the top of the yahoo page! Need some positive news as most recent.
btw Love Germany! I head there every other year when the F1 Race is in Nurburgring stay in Colonge and spend rest of time in Garmish, Fussen.
Shouldn't IMGN have had a press release on receiving FDA orphan status? Strange! Does it require an 8k filing?
Agreed! With Just Right getting out there also with there 5mm, they are both creating demand for less invasive staplers. CRDC is in a better position since Just Rights stapler really has no IP because it uses the "B" staple design and does not have the articulation of cardiac. They have sealing, which cardiac will also eventually have. With the ability to get down to 3mm with cardicas D staple, flex shaft, multi-fire etc they will have the most comprehensive product line. Questions is how far in the development will they get before being acquired. MLV did say they will be acquired once they complete development (may not mean approval) of their microcutter product line. Abbott has sold off their generic pharm rx business and stated they plan to go shopping for new medical devices. Can't expect Stryker to sit out of the autosuture market either. But I do not see one of the market leaders let this one get a way. It's with unequivocally the best IP available!
Sentiment: Strong Buy
Bio, I feel your pain and are also frustrated. How much of it is simply the steep challenges in science and especially oncology? I would be disappointed with the management team if we didn't have 17 clinical trials going on, 1 approval and 4 wholly owned with the who's who of oncology, had no focus and wasted money. If it was that bad, wouldn't also invite activists like Icahn and Ackerman? I feel we've been beat down much like HGSI after their Lupus approval then acquired by GSK. Things are being overly hyped with a negative slant.
I find it very strange they didn't post the Orphan Designation News.
This was from a seeking alpha article:
"A near term catalyst for an Immunogen stock price jump comes from the possibility of it being acquired. Recently, the company's executives filed an 8K form. The 8K form outlined the compensatory arrangement and departure process of officers in the event of a merger or consolidation. Immunogen may be acquired at any time this year given that it sits on $211 million in cash with no debt and that a widely expected FDA approval of T-DM1 is right around the corner."
Much to your chagrin stock grants were handed to sr leadership. Dan gets 210k, while lambert, Johnston and Morris get 100k. Directors like O'Leary get 80k all at $10.79
Slumdawg thanks for the quick analysis and facts! Much appreciated. Thanks for being a poster on this board, too quiet around here!
This suggests possible BOD shake up with their new 10% of influence.
"Broadfin Capital reports 9.98% stake in Cardica Broadfin Capital has recently engaged, and intend to continue to engage, in discussions with the company’s management and board of directors regarding the composition of the Board, generally, and means to enhance stockholder value."
I'm sure Broadfin sees possible catalysts just ahead such as Japan Microcutter Approval, Microcutter 45 exchange submission and possible ISRG DaVinci Microcutter. R&D surely has made progress since that original licensing deal.
Maybe Roche helping drive down IMGN Stock to acquire on the cheap, then drive Kadcyla with 100% ownership. GSK screwed HGSI with their Lupus drug in early launch driving the price down only to pick them up on the cheap.
The early sell for $1.03 was clearly someone trolling to see if they could line up more sellers. Didn't happen! Century Medical will be a catalyst as they have a strong sales force with reach something cardiac doesn't have in the USA. Japan also is a big on miniaturization and a less-invasive procedures. Cardica may also surprise with an earlier than anticipated submission for the 30 exchange short shaft and 45 microcutters. Each of these catalysts will cause analyst to revise targets.
Wedbush stated they have a $4.00 target on crdc when they introduced Bernard's presentation. He did a great job. Really emphasized they IP and mentioned more parents are forthcoming.
Not true, a major uptrend signal. The 50 day moving average has clearly crossed and sustained above the 200 moving average, aka the "Goldern Cross" which is a very bullish sign. Japan approval will push this over $1.40. Coming any day as it was filed last August. Wed Bush has a $4.00 target post the Q3 Earnings call
Bio, phase II is where the value creation and shareholder value begins. We have to get these wholly owned dosed right. I do believe that Sanofi (5 compounds, 1 phase II), Amgen (4 compounds) and Novartis are the likely targets. One has to look at big pharma's current oncology portfolio, type of cancer (ADC platform proven to work), patent expirations and annual sales. If IMGNs ADC can extent the patent life with a more effective and less toxic formula, the acquisition price for IMGN looks very reasonable.
Sanofi has this drug candidate in Phase 2, IMGN has it as Phase 1. It would be nice if they kept these up to date increasing the value of the pipeline. IMGN makes up almost 50% of Sanofi's Oncology Pipeline! Sanofi has bought REGN yet, so maybe their are happy with licensing deals. Interesting that they didn't comment on the Fast Track for IMGN853 and the advancement of their pipeline. They are conspicuous with their lack of investor communications!
Well one thing is clear, no one is buying on M& A speculation. The usual crowd of Biotechs rumored to be acquired are all up big today. Not us! But then again we are so quiet we've fallen off the radar.